Tharimmune (NASDAQ:THAR) Shares Up 15.2% – Here’s Why

Shares of Tharimmune, Inc. (NASDAQ:THAR) rose 15.2% during mid-day trading on Tuesday . The company traded as high as $2.77 and last traded at $2.65. Approximately 988,188 shares were traded during trading, a decline of 33% from the average daily volume of 1,476,877 shares. The stock had previously closed at $2.30.

Tharimmune Stock Performance

The stock has a fifty day simple moving average of $3.18 and a 200-day simple moving average of $3.42. The stock has a market cap of $111.30 million, a P/E ratio of -0.74 and a beta of 1.43.

Hedge Funds Weigh In On Tharimmune

A number of large investors have recently added to or reduced their stakes in THAR. XTX Topco Ltd bought a new position in Tharimmune during the 2nd quarter worth about $25,000. Drucker Wealth 3.0 LLC bought a new position in shares of Tharimmune during the 3rd quarter worth approximately $29,000. Essex LLC bought a new position in shares of Tharimmune during the 4th quarter worth approximately $31,000. Franklin Resources Inc. bought a new position in shares of Tharimmune during the 2nd quarter worth approximately $88,000. Finally, State Street Corp grew its stake in shares of Tharimmune by 109.0% during the 4th quarter. State Street Corp now owns 36,621 shares of the company’s stock worth $111,000 after acquiring an additional 19,100 shares in the last quarter. Institutional investors own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.